A Multicentric, Randomized, Double Blind, Parallel Group, Two Arm, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Manda Koso versus Placebo in patients with immune deficiency.

开始日期2023-04-13

申办/合作机构

THINQ Pharma-CRO Ltd.

[+1]

CTRI/2021/04/032987 / Not yet recruiting临床3期

A Prospective, Observational, Randomized, Open labeled, Multi Center, Parallel-Group, Two arm, Clinical trial Study to Evaluate the Efficacy, Safety and Tolerability of Renochlor Formulation as an add on to the Standard of care for the Management of Chronic Renal Failure (CRF)

开始日期2021-04-26

申办/合作机构

THINQ Pharma-CRO Ltd.

CTRI/2021/03/032471 / CompletedN/A

A Non-Interventional, Retrospective, Observational Study to Analyze Safety, Efficacy and Tolerability of THINQURE 20 in COVID-19 Patients.

开始日期2021-04-12

申办/合作机构

THINQ Pharma-CRO Ltd.

100 项与 THINQ Pharma-CRO Ltd. 相关的临床结果

登录后查看更多信息

0 项与 THINQ Pharma-CRO Ltd. 相关的专利（医药）

登录后查看更多信息

项与 THINQ Pharma-CRO Ltd. 相关的文献（医药）

2024-03-13·Coronaviruses

Clinical Trial to Evaluate Safety and Efficacy of Thinqure20 (A Herbal Composition) in the Treatment and Prophylaxis of Novel Coronavirus and Testing its In vitro- Potential against MS2 Bacteriophagae, Corona Virus, Influenza Virus and Mucor racemosus

作者: Dhawal, Pranjali P ; Varma, Nikhil ; Rangnekar, Hrishikesh ; Gharpure, Milind

Background and Objective:Thinqure20 is a polyherbal, reverse-pharmacology-based formulation that contains Piper longum, Piper nigrum, Zingiber officinale, and rock salt as active ingredients. It is designed to work as an effective antiviral agent and also as a preventive measure against SARS-CoV-2. Clinical and non-clinical studies have established significant safety efficacy and tolerability of Thinqure20 formulation in the treatment of COVID-19 infection.Methods:In vivo human study was conducted on COVID-19 patients for 5 days. A total of 30 Covid-19 patients (n = 30) were enrolled. In vitro, cell line studies were also carried out to evaluate the potential effectiveness of Thinqure20 polyherbal formulation as an antiviral, antifungal, and Angiotensin- Converting Enzyme 2 (ACE2) inhibition.Results:Human studies have demonstrated a mean percentage of reduction in viral load from baseline to end of the study visit which was found to be 75.4%. The minimum and maximum reduction in viral load was found to be 59.3% and 100%, respectively. Viral load testing was carried out by Reverse Transcriptase-quantitative Polymerase Chain Reaction (RT-qPCR) test. In vitro studies of Thinqure, 20 extracts showed potential antiviral activity against MS2 bacteriophage, influenza, and human coronavirus, antifungal activity against Mucor racemosus, and significant ACE2 receptor inhibition.Conclusion:Thinqure20, a polyherbal formulation, is a potentially effective antiviral agent against non-enveloped viruses (MS2 bacteriophage), enveloped viruses (influenza and human coronavirus), and antifungal agent against mucor strains. It is also proven to be effective in the treatment of COVID-19 and can be attributed to an early recovery by the reduction in viral load.Clinical Trail Registration Number:CTRI/2021/03/032471.

2020-11-01·Naunyn-Schmiedeberg's Archives of Pharmacology4区 · 医学

Sodium copper chlorophyllin attenuates adenine-induced chronic kidney disease via suppression of TGF-beta and inflammatory cytokines

4区 · 医学

Article

作者: Suryavanshi, Sachin V ; Kulkarni, Yogesh A ; Gharpure, Milind

The present study was designed to evaluate the effect of sodium copper chlorophyllin (SCC) in adenine-induced chronic kidney disease (CKD). CKD was induced in male Wistar rats by feeding 0.3% w/w adenine diet for 28 days. After induction, animals were treated with sodium copper chlorophyllin at dose 2.7, 5.4, and 10.8 mg/kg for the next 28 days. The biochemical and urines parameters like creatinine, blood urea nitrogen (BUN), albumin, total protein creatinine clearance, urea clearance, and glomerular filtration rate were assessed on days 0, 14, and 28. Plasma TGF-β1, COX-2, and IL-6 levels were assessed. Various oxidative stress parameters and TGF-β1 expression were determined in the kidney. Histopathology of the kidney was studied with different stains. Sodium copper chlorophyllin-treated animals showed a significant reduction in urine output and relative kidney weight. The treatment with sodium copper chlorophyllin significantly improved kidney function by normalizing biochemical and urine parameters. Treatment with SCC significantly reduced circulatory inflammatory mediators-TGF-β1, COX-2, and IL-6. Additionally, the treatment also significantly reduced oxidative stress and TGF-β1 expression in kidney tissues. Histopathology studies showed inhibition in the kidney damage due to the treatment of SCC. The sodium copper chlorophyllin treatment attenuated adenine-induced chronic kidney disease in rats.

Clinical and non-clinical exploration of Thinqure20 (a herbal composition) in treatment and prophylaxis of novel coronavirus and in other pathogens.

作者: Mote, Ravindra ; Nikhil ; Dhawal, Pranjali ; ranganekar, Hrishikesh ; vekariya, Sanjay ; Gulgule, Ravindra ; Gharpure, Milind

AbstractObjective Ongoing pandemic is being tackled by many in many ways. Simple yet effective age-old formulations might hold a key in better management of the disease. Objective was to run a series of studies to make and explore one such formulation through reverse-pharmacology. Thinqure 20 is a polyherbal formulation that contains Piper longum, Piper nigrum, Zingiber officinale, and rock salt. Thinqure20 was designed to work as an antiviral drug, especially against SARS CoV-2 virus. Hence the present Clinical and subsequent non-clinical studies were carried-out to evaluate efficacy, safety and tolerability of Thinqure 20 in Covid-19 infection. Methods Clinical study was conducted to evaluate safety, efficacy and tolerability of Thinqure 20 in Covid-19 patients (CTRI/2021/03/032471). The treatment duration was 5 days. Patients were assessed for efficacy, safety, and tolerability of Thinqure20. Subsequently, non-clinical in-vitro cell line study, antiviral and antifungal, COVID SPIKE ACE2 inhibition studies were done on Thinqure20 extract. ASTM guidelines were followed for the same. Results The clinical study showed the mean percentage reduction in the viral load from baseline to end of the study visit of Thinqure 20 to be 75.4%, where the minimum reduction was 59.3%, while the maximum reduction in viral load was 100%. There were 04 clinical adverse events reported which were mild in nature. Viral load testing was done by Quantitative RT-qPCR for SARS-CoV-2 (Covid-19) RNA method from NABL accredited lab. A total of 30 patients were enrolled in the study. 29 patients completed the study. In the invitro study on cell-line, the extract showed potential antiviral activity against MS2 bacteriophage, a non-enveloped virus, influenza virus, and human coronavirus with IC90 value at > 10mg/ml. The sample also presented antifungal ability against Mucor racemosus with EC50 value at concentration 1mg/ml. Thinqure 20 was tested for its ACE2 receptor inhibitory activity. ). The kit-based SARS inhibitor showed 89.00% ACE 2 receptor inhibition when used as per KIT’s instructions. Conclusion The results showed that Thinqure 20 has potential against non-enveloped viruses and enveloped viruses including human coronavirus. It also showed antifungal activity against mucor strain. Evidences support that the use of Thinqure 20 has beneficial effects in the treatment of Covid19 which may be linked to a decrease in total viral load in patients. It provided better relief for the recovery of the COVID-19 disease.

100 项与 THINQ Pharma-CRO Ltd. 相关的药物交易

登录后查看更多信息

100 项与 THINQ Pharma-CRO Ltd. 相关的转化医学

登录后查看更多信息